CABA (Cabaletta Bio) Short-Term Debt: $0.00 Mil (As of Mar. 2026)


CABA Cabaletta Bio Inc CABA
34 GF Score
Price $3.13
! 1 Warning Sign
View Full Analysis

What is Cabaletta Bio Short-Term Debt?

Cabaletta Bio CABA +1.29% 34 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Cabaletta Bio's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Cabaletta Bio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Cabaletta Bio Short-Term Debt Related Terms

Cabaletta Bio Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Cabaletta Bio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabaletta Bio Short-Term Debt Chart

Cabaletta Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cabaletta Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CABA
34GF Score
Cabaletta Bio Inc CABA
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Cabaletta Bio (CABA) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is Cabaletta Bio's Short-Term Debt too high?
Cabaletta Bio's current Short-Term Debt is $0.00 Mil. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's Short-Term Debt compare to RZLT and CCCC?
Cabaletta Bio's Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Cabaletta Bio's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cabaletta Bio Business Description

Other Exchanges CABA:Mexico
Address 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score

Get the complete analysis for CABA

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.13
Price